Just FYI, today's update of the RBS rating:
RBS Australia rates ACL as Buy (1) -
Target $1.30 (was $0.83). Alchemia is preparing Phase II trials and on the news the broker has factored some upside from positive results into its forecasts. The changes mean an increase in price target.
Regulatory approval for a generic fondaparinux product is pending and the broker expects approval will be a positive catalyst for the stock. Buy rating retained.
Target price is $1.30 Current Price is $0.63 Difference: $0.67
If ACL meets the RBS Australia target it will return approximately 106% (excluding dividends, fees and charges).
rbs rating update
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable